ArticleProtein science : a publication of the Protein Society2025
An engineered redox-switchable streptavidin mutein enables the high-affinity capture and efficient elution of biotinylated ligands.
Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An engineered streptavidin condensate platform for chemically inducible control of endogenous proteins in mammalian cells.bioRxiv : the preprint server for biology · 2026Article
- An engineered redox-switchable streptavidin mutein enables the high-affinity capture and efficient elution of biotinylated ligands.Protein science : a publication of the Protein Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Although the high affinity and specificity of the interaction between streptavidin and biotin are widely utilized to isolate biotinylated ligands, their elution over practical timescales requires the use of strongly denaturing conditions that are incompatible with many target biomolecules. To overcome this limitation, we previously engineered a disulfide bond into a critical loop of streptavidin to create the redox-sensitive M88 mutein, which releases biotinylated ligands ~19,000-fold faster in the reduced state when compared with the oxidized state. To optimize the speed and efficiency of ligand recovery, we describe how multiple mechanisms like disulfide bond reduction, increasing temperature, elevating pH, and adding organic cosolvents can dramatically increase the rates of dissociation for different types of biotinylated ligands bound to M88 or wild-type streptavidin coupled to magnetic beads. By combining these mechanisms, we demonstrate how a range of biotinylated biomolecules (peptide, oligonucleotide, and protein) can be efficiently recovered under mild conditions that preserve biological activity. M88 magnetic beads thus provide many advantages over currently available methods using either wild-type streptavidin or lower affinity biotin-binding proteins for applications requiring both high affinity capture and efficient release of target biomolecules under non-denaturing conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.